<p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）股票在周五的午盘交易中上涨了 6.2%，因为 BTIG 研究将该股票的目标价从 7.00 美元上调至 9.00 美元。BTIG 研究目前对该股票给予买入评级。Organogenesis 的交易最高价为 5.48 美元，最后交易价为 5.4350 美元。在交易过程中，约有 215,220 股成交，较日均成交量 1,433,693 股下降了 85%。该股票此前收盘价为 5.12 美元。</p>
<p>ORGO 已经成为其他几份报告的主题。Cantor Fitzgerald 在 8 月 8 日的研究报告中将 Organogenesis 的目标价从 7.00 美元上调至 9.00 美元，并给予该股票 “超配” 评级。Wall Street Zen 在 11 月 8 日的研究报告中将 Organogenesis 的评级从 “持有” 上调至 “强力买入”。最后，Weiss Ratings 在 11 月 13 日的研究报告中重申了对 Organogenesis 的 “卖出（d+）” 评级。有两位分析师对该股票给予买入评级，一位给予持有评级，一位给予卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，共识目标价为 8.00 美元。</p>
<p>获取 <strong>Organogenesis</strong> 警报：</p>
<p><strong>查看我们关于 Organogenesis 的最新研究报告</strong></p>
<h2>对 Organogenesis 的对冲基金看法</h2>
<p>大型投资者最近对该公司的持仓进行了调整。Trexquant Investment LP 在第一季度购买了 Organogenesis 的新股份，价值约 516,000 美元。Assenagon Asset Management S.A.在第二季度将其在 Organogenesis 的持股增加了 748.1%。Assenagon Asset Management S.A.目前拥有 2,857,904 股该公司的股票，价值 10,460,000 美元，此前在上个季度又收购了 2,520,941 股。Cerity Partners LLC 在第一季度将其在 Organogenesis 的持股增加了 48.2%。Cerity Partners LLC 目前拥有 74,880 股该公司的股票，价值 323,000 美元，此前在上个季度又收购了 24,362 股。Vanguard Group Inc.在第一季度将其在 Organogenesis 的持股增加了 23.4%。Vanguard Group Inc.目前拥有 4,431,414 股该公司的股票，价值 19,144,000 美元，此前在上个季度又收购了 841,618 股。最后，Connor Clark &amp; Lunn Investment Management Ltd.在第一季度将其在 Organogenesis 的持股增加了 45.3%。Connor Clark &amp; Lunn Investment Management Ltd.目前拥有 667,529 股该公司的股票，价值 2,884,000 美元，此前在上个季度又收购了 208,038 股。49.57% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>Organogenesis 价格表现</h2>
<p>该公司的 50 日移动平均价格为 4.61 美元，200 日移动平均价格为 4.27 美元。该公司的速动比率为 2.88，流动比率为 3.32，债务与股本比率为 0.01。该股票的市值为 6.961 亿美元，市盈率为-45.54，贝塔值为 1.68。</p>
<p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）最近在 11 月 6 日公布了季度财报。该公司报告季度每股收益为 0.18 美元，超出市场共识预期的 0.07 美元，超出幅度为 0.11 美元。该公司季度收入为 1.5086 亿美元，而市场共识预期为 1.3410 亿美元。Organogenesis 的净利润率为-1.30%，股本回报率为 4.01%。Organogenesis 已设定 2025 财年的每股收益指导。分析师预计 Organogenesis 在当前年度的每股收益为-0.07 美元。</p>
<h2>关于 Organogenesis</h2>
<p>（获取免费报告）</p>
<p>Organogenesis Holdings Inc 是一家再生医学公司，开发、制造和商业化用于美国先进伤口护理、外科和运动医学市场的解决方案。该公司的先进伤口护理产品包括 Affinity，一种保留了活细胞、生长因子/细胞因子和原生组织中细胞外基质蛋白的羊膜；Novachor，一种保留了活细胞、生长因子/细胞因子和原生组织中细胞外基质蛋白的绒毛膜；Apligraf，一种生物工程活细胞疗法，产生多种细胞因子和生长因子；Dermagraft，一种生物工程产品，产生人类胶原蛋白、细胞外基质、蛋白质、细胞因子和生长因子；NuShield，脱水的胎盘组织覆盖羊膜和绒毛膜，用于保持海绵/中间层完整；以及 PuraPly AM，一种抗菌屏障，能够实现适应性和液体排放。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Organogenesis</li>
<li>便士股票适合你的投资组合吗？</li>
<li>4 只值得关注的高风险成长股，价格低于 15 美元</li>
<li>CD 计算器：定期存款计算器</li>
<li>沃尔玛股票在强劲的第三季度后飙升——未来增长更强劲</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>微软的 AI 超级工厂可能推动股票反弹</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Organogenesis 吗？</h2>
<p>在考虑 Organogenesis 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Organogenesis 并不在名单上。</p>
<p>虽然 Organogenesis 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ORGO

<p>Organogenesis（纳斯达克代码：ORGO）股价上涨 6.2%，在 BTIG Research 将其目标价从 7.00 美元上调至 9.00 美元，并维持买入评级后，该股交易价格为 5.48 美元，交易量有所下降。分析师的评级意见不一，市场共识目标价为 8.00 美元。对冲基金增加了持股，持有该股票的比例为 49.57%。Organogenesis 报告的季度收益好于预期，收入为 1.5086 亿美元</p>

<p>Organogenesis (NASDAQ:ORGO - Get Free Report) shares rose 6.2% during mid-day trading on Friday after BTIG Research raised their price target on the stock from $7.00 to $9.00. BTIG Research currently has a buy rating on the stock. Organogenesis traded as high as $5.48 and last traded at $5.4350. Approximately 215,220 shares traded hands during trading, a decline of 85% from the average daily volume of 1,433,693 shares. The stock had previously closed at $5.12.</p>
<div class="lb-trans"><p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）股票在周五的午盘交易中上涨了 6.2%，因为 BTIG 研究将该股票的目标价从 7.00 美元上调至 9.00 美元。BTIG 研究目前对该股票给予买入评级。Organogenesis 的交易最高价为 5.48 美元，最后交易价为 5.4350 美元。在交易过程中，约有 215,220 股成交，较日均成交量 1,433,693 股下降了 85%。该股票此前收盘价为 5.12 美元。</p>
</div><p>ORGO has been the topic of several other reports. Cantor Fitzgerald raised their target price on Organogenesis from $7.00 to $9.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, August 8th. Wall Street Zen raised shares of Organogenesis from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Organogenesis in a research report on Thursday, November 13th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and a consensus price target of $8.00.</p>
<div class="lb-trans"><p>ORGO 已经成为其他几份报告的主题。Cantor Fitzgerald 在 8 月 8 日的研究报告中将 Organogenesis 的目标价从 7.00 美元上调至 9.00 美元，并给予该股票 “超配” 评级。Wall Street Zen 在 11 月 8 日的研究报告中将 Organogenesis 的评级从 “持有” 上调至 “强力买入”。最后，Weiss Ratings 在 11 月 13 日的研究报告中重申了对 Organogenesis 的 “卖出（d+）” 评级。有两位分析师对该股票给予买入评级，一位给予持有评级，一位给予卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，共识目标价为 8.00 美元。</p>
</div><p>Get <strong>Organogenesis</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Organogenesis</strong> 警报：</p>
</div><p><strong>View Our Latest Research Report on Organogenesis</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Organogenesis 的最新研究报告</strong></p>
</div><h2>Hedge Funds Weigh In On Organogenesis</h2>
<div class="lb-trans"><h2>对 Organogenesis 的对冲基金看法</h2>
</div><p>Large investors have recently made changes to their positions in the business. Trexquant Investment LP purchased a new stake in shares of Organogenesis in the 1st quarter worth approximately $516,000. Assenagon Asset Management S.A. boosted its holdings in Organogenesis by 748.1% in the second quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company's stock worth $10,460,000 after acquiring an additional 2,520,941 shares in the last quarter. Cerity Partners LLC boosted its holdings in Organogenesis by 48.2% in the first quarter. Cerity Partners LLC now owns 74,880 shares of the company's stock worth $323,000 after acquiring an additional 24,362 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Organogenesis by 23.4% in the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock worth $19,144,000 after acquiring an additional 841,618 shares during the last quarter. Finally, Connor Clark &amp; Lunn Investment Management Ltd. increased its holdings in shares of Organogenesis by 45.3% during the first quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 667,529 shares of the company's stock valued at $2,884,000 after acquiring an additional 208,038 shares in the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近对该公司的持仓进行了调整。Trexquant Investment LP 在第一季度购买了 Organogenesis 的新股份，价值约 516,000 美元。Assenagon Asset Management S.A.在第二季度将其在 Organogenesis 的持股增加了 748.1%。Assenagon Asset Management S.A.目前拥有 2,857,904 股该公司的股票，价值 10,460,000 美元，此前在上个季度又收购了 2,520,941 股。Cerity Partners LLC 在第一季度将其在 Organogenesis 的持股增加了 48.2%。Cerity Partners LLC 目前拥有 74,880 股该公司的股票，价值 323,000 美元，此前在上个季度又收购了 24,362 股。Vanguard Group Inc.在第一季度将其在 Organogenesis 的持股增加了 23.4%。Vanguard Group Inc.目前拥有 4,431,414 股该公司的股票，价值 19,144,000 美元，此前在上个季度又收购了 841,618 股。最后，Connor Clark &amp; Lunn Investment Management Ltd.在第一季度将其在 Organogenesis 的持股增加了 45.3%。Connor Clark &amp; Lunn Investment Management Ltd.目前拥有 667,529 股该公司的股票，价值 2,884,000 美元，此前在上个季度又收购了 208,038 股。49.57% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>Organogenesis Price Performance</h2>
<div class="lb-trans"><h2>Organogenesis 价格表现</h2>
</div><p>The firm has a fifty day moving average price of $4.61 and a two-hundred day moving average price of $4.27. The company has a quick ratio of 2.88, a current ratio of 3.32 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $696.10 million, a P/E ratio of -45.54 and a beta of 1.68.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 4.61 美元，200 日移动平均价格为 4.27 美元。该公司的速动比率为 2.88，流动比率为 3.32，债务与股本比率为 0.01。该股票的市值为 6.961 亿美元，市盈率为-45.54，贝塔值为 1.68。</p>
</div><p>Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.07 by $0.11. The company had revenue of $150.86 million for the quarter, compared to the consensus estimate of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. Organogenesis has set its FY 2025 guidance at EPS. On average, analysts expect that Organogenesis will post -0.07 EPS for the current year.</p>
<div class="lb-trans"><p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）最近在 11 月 6 日公布了季度财报。该公司报告季度每股收益为 0.18 美元，超出市场共识预期的 0.07 美元，超出幅度为 0.11 美元。该公司季度收入为 1.5086 亿美元，而市场共识预期为 1.3410 亿美元。Organogenesis 的净利润率为-1.30%，股本回报率为 4.01%。Organogenesis 已设定 2025 财年的每股收益指导。分析师预计 Organogenesis 在当前年度的每股收益为-0.07 美元。</p>
</div><h2>About Organogenesis</h2>
<div class="lb-trans"><h2>关于 Organogenesis</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.</p>
<div class="lb-trans"><p>Organogenesis Holdings Inc 是一家再生医学公司，开发、制造和商业化用于美国先进伤口护理、外科和运动医学市场的解决方案。该公司的先进伤口护理产品包括 Affinity，一种保留了活细胞、生长因子/细胞因子和原生组织中细胞外基质蛋白的羊膜；Novachor，一种保留了活细胞、生长因子/细胞因子和原生组织中细胞外基质蛋白的绒毛膜；Apligraf，一种生物工程活细胞疗法，产生多种细胞因子和生长因子；Dermagraft，一种生物工程产品，产生人类胶原蛋白、细胞外基质、蛋白质、细胞因子和生长因子；NuShield，脱水的胎盘组织覆盖羊膜和绒毛膜，用于保持海绵/中间层完整；以及 PuraPly AM，一种抗菌屏障，能够实现适应性和液体排放。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Organogenesis</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>4 High-Risk Growth Stocks Under $15 to Watch This Fall</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Walmart Stock Surges After a Solid Q3—Stronger Growth Ahead</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Microsoft’s AI Superfactory Could Power a Stock Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Organogenesis</li>
<li>便士股票适合你的投资组合吗？</li>
<li>4 只值得关注的高风险成长股，价格低于 15 美元</li>
<li>CD 计算器：定期存款计算器</li>
<li>沃尔玛股票在强劲的第三季度后飙升——未来增长更强劲</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>微软的 AI 超级工厂可能推动股票反弹</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Organogenesis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Organogenesis 吗？</h2>
</div><p>Before you consider Organogenesis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Organogenesis 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Organogenesis 并不在名单上。</p>
</div><p>While Organogenesis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Organogenesis 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Organogenesis（NASDAQ: ORGO）因分析师上调评级而股价上涨 6.2%